Regulatory Post-Marketing Surveillance (rPMS) of Xolair® (Xolair® 150mg Powder for Solution for Injection, Xolair® 150mg/1ml Liquid in Pre-filled Syringe, Xolair® 75mg/0.5ml Liquid in Pre-filled Syringe) for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Latest Information Update: 24 Jun 2025
At a glance
- Drugs Omalizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Adverse reactions
- Sponsors Novartis
Most Recent Events
- 15 Jun 2025 Status changed from active, no longer recruiting to completed.
- 18 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 11 Mar 2025 Planned End Date changed from 31 Jan 2025 to 15 Apr 2025.